The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma

Cancer Biology and Therapy

Volumn 16, Issue 6, 2015, Pages 949-957

  Hu, Yafang ^a,b   Bobb, Daniel ^a   He, Jianping ^a   Hill, D Ashley ^a   Dome, Jeffrey S ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Alvespimycin; HSP90; Imetelstat; Osteosarcoma; Telomerase

Indexed keywords

ALVESPIMYCIN; ATM PROTEIN; CASPASE 3; HEAT SHOCK PROTEIN 90; HISTONE H2AX; IMETELSTAT; PLACEBO; PROTEIN P53; TELOMERASE; 17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; ENZYME INHIBITOR; INDOLE DERIVATIVE; MACROCYCLIC LACTAM; NICOTINAMIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PROTEIN CLEAVAGE; TELOMERE SHORTENING; TUMOR GROWTH; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INDOLES; LACTAMS, MACROCYCLIC; MICE; NIACINAMIDE; OSTEOSARCOMA; SIGNAL TRANSDUCTION; TELOMERASE; TELOMERE SHORTENING; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943774273     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1040964     Document Type: Article

References (41)

1. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, et al. SEER Cancer Statistics Review, 1975-2008, 2011; http://seer. cancer. gov/csr/1975_2011/.
2. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 2003; 9: 5442-53; PMID: 14654523.
3. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005; 19: 2100-10; PMID: 16166375; http://dx. doi. org/10. 1101/gad. 1346005.
4. Harley CB. Telomere loss: mitotic clock or genetic time bomb. Mutat Res 1991; 256: 271-82; PMID: 1722017; http://dx. doi. org/10. 1016/0921-8734(91)90018-7.
5. Bakkenist CJ, Drissi R, Wu J, Kastan MB, Dome JS. Disappearance of the telomere dysfunction-induced stress response in fully senescent cells. Cancer Res 2004; 64: 3748-52; PMID: 15172978; http://dx. doi. org/10. 1158/0008-5472. CAN-04-0453.
6. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, von Zglinicki T, Saretzki G, Carter NP, Jackson SP. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426: 194-8; PMID: 14608368; http://dx. doi. org/10. 1038/nature02118.
7. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer [see comments]. Science 1994; 266: 2011-5; PMID: 7605428; http://dx. doi. org/10. 1126/science. 7605428.
8. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 2003; 63: 1759-63; PMID: 12702558.
9. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 2004; 22: 3790-7; PMID: 15365076; http://dx. doi. org/10. 1200/JCO. 2004. 03. 043.
10. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8: 167-79; PMID: 18256617; http://dx. doi. org/10. 1038/nrc2275.
11. Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW, Gryaznov SM. Lipid modification of GRN163, an N30!P50 thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005; 24: 5262-8; PMID: 15940257; http://dx. doi. org/10. 1038/sj. onc. 1208760.
12. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 2005: 1-9; PMID: 16319992.
13. Dikmen ZG, Wright WE, Shay JW, Gryaznov SM. Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells. J Cell Biochem 2008; 104: 444-52; PMID: 18044713; http://dx. doi. org/10. 1002/jcb. 21635.
14. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, Mickey BE, Wright WE, Shay JW, Bachoo RM. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010; 16: 154-63; PMID: 20048334; http://dx. doi. org/10. 1158/1078-0432. CCR-09-2850.
15. Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S, Yamashita Y, Pongracz K, Pruzan R, Wunder E, Piatyszek M, Li S, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 2003; 63: 3931-9; PMID: 12873987.
16. Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Gryaznov S, Moore MA. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004; 103: 258-66; PMID: 12969977; http://dx. doi. org/10. 1182/blood-2003-02-0546.
17. Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008; 22: 1410-8; PMID: 18449204; http://dx. doi. org/10. 1038/leu. 2008. 81.
18. Hu Y, Bobb D, Lu Y, He J, Dome JS. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor. Cancer Genet 2014; 207: 403-11; PMID: 25441685; http://dx. doi. org/10. 1016/j. cancergen. 2014. 09. 002.
19. Huff CA, Wang Q, Badros AZ, Jones RJ, Reddy A, Nishimoto K, Stuart MJ, Kelsey SM, Matsui W. The telomerase inhibitor, imetelstat, rapidly reduces myeloma cancer stem cells (CSCs) in a phase II trial. ASH Ann Meet Abstr 2012; 120: 4898.
20. Baerlocher GM, E. O. L, Ayran C, Blaney M, Burington B, Morfeld D, Olatoyosi O, Ottman O, Reddy A, Roeth A, et al. Imetelstat rapidly induces and maintains substantial hematologic and molecular responses in patients with essential thrombocythemia (ET) who are refractory or intolerant to prior therapy: preliminary phase II results. Congr Eur Hematol Assoc 2013; abstract # 4398.
21. Williams SC. No end in sight for telomerase-targeted cancer drugs. Nat Med 2013; 19: 6; PMID: 23295993; http://dx. doi. org/10. 1038/nm0113-6.
22. Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, Blais N, Von Pawel J, Hart L, Reck M, et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Annals Oncol 2015; 26: 354-62; PMID: 25467017; http://dx. doi. org/10. 1093/annonc/mdu550.
23. Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Lin T, Weigel BJ, et al. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res 2013; 19: 6578-84; PMID: 24097866; http://dx. doi. org/10. 1158/1078-0432. CCR-13-1117.
24. Aisner DL, Wright WE, Shay JW. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev 2002; 12: 80-5; PMID: 11790559; http://dx. doi. org/10. 1016/S0959-437X(01)00268-4.
25. Keppler BR, Grady AT, Jarstfer MB. The biochemical role of the heat shock protein 90 chaperone complex in establishing human telomerase activity. J Biol Chem 2006; 281: 19840-8; PMID: 16714764; http://dx. doi. org/10. 1074/jbc. M511067200.
26. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004; 3: 1021-30; PMID: 15299085; http://dx. doi. org/10. 4161/cbt. 3. 10. 1142.
27. Jego G, Hazoume A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett 2013; 332: 275-85; PMID: 21078542; http://dx. doi. org/10. 1016/j. canlet. 2010. 10. 014.
28. Villa R, Folini M, Porta CD, Valentini A, Pennati M, Daidone MG, Zaffaroni N. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis 2003; 24: 851-9; PMID: 12771028; http://dx. doi. org/10. 1093/carcin/bgg028.
29. Compton SA, Elmore LW, Haydu K, Jackson-Cook CK, Holt SE. Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of hsp90 in human tumor cells. Mol Cell Biol 2006; 26: 1452-62; PMID: 16449656; http://dx. doi. org/10. 1128/MCB. 26. 4. 1452-1462. 2006.
30. Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, Akpan A, Yang A, Zvelebil M, Cramer R, Stimson L, et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2007; 67: 3239-53; PMID: 17409432; http://dx. doi. org/10. 1158/0008-5472. CAN-06-2968.
31. Bryan TM, Englezou A, Dallapozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3: 1271-4; PMID: 9359704; http://dx. doi. org/10. 1038/nm1197-1271.
32. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14: 4240-8; PMID: 7556065.
33. Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 2004; 164: 1523-9; PMID: 15111298; http://dx. doi. org/10. 1016/S0002-9440(10)63710-8.
34. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, Gorlick R, Meyers P, Healey JH, Ladanyi M. Divergent patterns of telomere maintenance mechanisms among human sarcomas: Sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 2004; 41: 155-62; PMID: 15287028; http://dx. doi. org/10. 1002/gcc. 20074.
35. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001; 107: 67-77; PMID: 11595186; http://dx. doi. org/10. 1016/S0092-8674(01)00504-9.
36. Jackson SR, Zhu CH, Paulson V, Watkins L, Dikmen ZG, Gryaznov SM, Wright WE, Shay JW. Antiadhesive effects of GRN163L-an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase. Cancer Res 2007; 67: 1121-9; PMID: 17283146; http://dx. doi. org/10. 1158/0008-5472. CAN-06-2306.
37. Mender I, Senturk S, Ozgunes N, Akcali KC, Kletsas D, Gryaznov S, Can A, Shay JW, Dikmen ZG. Imetelstat (a telomerase antagonist) exerts offtarget effects on the cytoskeleton. Int J Oncol 2013; 42: 1709-15; PMID: 23545855.
38. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, Ouellette M, Trager JB, Morin GB, Toft DO, Shay JW, et al. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 1999; 13: 817-26; PMID: 10197982; http://dx. doi. org/10. 1101/gad. 13. 7. 817.
39. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13: 1549-56; PMID: 12956959; http://dx. doi. org/10. 1016/S0960-9822(03)00542-6.
40. Dote H, Burgan WE, Camphausen K, Tofilon PJ. Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res 2006; 66: 9211-20; PMID: 16982765; http://dx. doi. org/10. 1158/0008-5472. CAN-06-2181.
41. Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 2006; 96: 73-81; PMID: 16319992; http://dx. doi. org/10. 1007/s10549-005-9043-5.